|
🐜
|
Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer.
18 auth.
C. Sternberg,
K. Fizazi,
F. Saad,
N. Shore,
U. de Giorgi,
D. Penson,
U. Ferreira,
E. Efstathiou,
K. Madziarska,
M. Kolinsky,
...
D. Cubero,
B. Noerby,
F. Zohren,
Xun Lin,
K. Modelska,
J. Sugg,
J. Steinberg,
M. Hussain
|
8 |
2020 |
8
🐜
|
|
🐜
|
Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation
16 auth.
T. Schroeder,
A. Czibere,
U. Platzbecker,
G. Bug,
L. Uharek,
T. Luft,
A. Giagounidis,
F. Zohren,
I. Bruns,
C. Wolschke,
...
K. Rieger,
R. Fenk,
U. Germing,
R. Haas,
N. Kröger,
G. Kobbe
|
7 |
2013 |
7
🐜
|
|
🦁
|
The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans.
F. Zohren,
Diamandis Toutzaris,
Viola Klärner,
H. Hartung,
B. Kieseier,
R. Haas
|
7 |
2008 |
7
🦁
|
|
🐜
|
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.
21 auth.
E. Pujade-Lauraine,
K. Fujiwara,
J. Ledermann,
A. Oza,
R. Kristeleit,
I. Ray-Coquard,
G. Richardson,
C. Sessa,
K. Yonemori,
Susana Banerjee,
...
A. Leary,
A. Tinker,
K. Jung,
R. Mądry,
Sang-Yoon Park,
C. Anderson,
F. Zohren,
R. Stewart,
Caimiao Wei,
S. Dychter,
B. Monk
|
7 |
2021 |
7
🐜
|
|
🐜
|
Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial
21 auth.
N. Agarwal,
A. Azad,
J. Carles,
A. Fay,
N. Matsubara,
D. Heinrich,
C. Szczylik,
U. Giorgi,
J. Joung,
P. Fong,
...
E. Voog,
Robert J Jones,
N. Shore,
C. Dunshee,
S. Zschäbitz,
J. Oldenburg,
Xun Lin,
C. Healy,
N. D. Santo,
F. Zohren,
K. Fizazi
|
7 |
2023 |
7
🐜
|
|
🐜
|
Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer
16 auth.
A. Armstrong,
A. Azad,
T. Iguchi,
R. Szmulewitz,
D. Petrylak,
J. Holzbeierlein,
A. Villers,
A. Alcaraz,
B. Alekseev,
N. Shore,
...
F. Gómez‐Veiga,
B. Rosbrook,
F. Zohren,
S. Yamada,
G. Haas,
A. Stenzl
|
7 |
2022 |
7
🐜
|
|
🐜
|
5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis
12 auth.
A. Czibere,
I. Bruns,
N. Kröger,
U. Platzbecker,
J. Lind,
F. Zohren,
...
R. Fenk,
U. Germing,
Thomas Schröder,
T. Gräf,
Rainer Haas,
G. Kobbe
|
6 |
2010 |
6
🐜
|
|
🐜
|
TAK‐228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non‐Hodgkin lymphoma, or Waldenström's macroglobulinemia
9 auth.
I. Ghobrial,
D. Siegel,
R. Vij,
J. Berdeja,
P. Richardson,
R. Neuwirth,
...
C. Patel,
F. Zohren,
J. Wolf
|
6 |
2016 |
6
🐜
|
|
🐜
|
Multiple myeloma-related deregulation of bone marrow-derived CD34(+) hematopoietic stem and progenitor cells.
22 auth.
I. Bruns,
Ron-Patrick Cadeddu,
Ines Brueckmann,
J. Fröbel,
Stefanie Geyh,
S. Buest,
J. Fischer,
F. Roels,
C. Wilk,
F. Schildberg,
...
A. Hünerlitürkoglu,
C. Zilkens,
M. Jäger,
U. Steidl,
F. Zohren,
R. Fenk,
G. Kobbe,
B. Brors,
A. Czibere,
T. Schroeder,
A. Trumpp,
R. Haas
|
6 |
2012 |
6
🐜
|
|
🐬
|
Successful treatment of relapsed AML after allogeneic stem cell transplantation with azacitidine.
T. Graef,
A. Kuendgen,
R. Fenk,
F. Zohren,
R. Haas,
G. Kobbe
|
6 |
2007 |
6
🐬
|
